Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 2.35 | 1.87 |
NAV | ₹16.26 | ₹39.94 |
Fund Started | 18 Oct 2021 | 25 Jun 2018 |
Fund Size | ₹226.50 Cr | ₹6226.82 Cr |
Exit Load | Exit load of 0.50%, if redeemed within 3 months. | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | -4.66% | 2.37% |
3 Year | 18.42% | 26.17% |
5 Year | - | 20.20% |
1 Year
3 Year
5 Year
Equity | 98.53% | 97.55% |
Cash | 1.47% | 2.45% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.62% |
Divi's Laboratories Ltd. | 7.79% |
Apollo Hospitals Enterprise Ltd. | 5.81% |
Max Healthcare Institute Ltd. | 5.70% |
Cohance Lifesciences Ltd. | 5.06% |
Torrent Pharmaceuticals Ltd. | 4.59% |
Fortis Healthcare Ltd. | 4.13% |
Aurobindo Pharma Ltd. | 3.62% |
Aster DM Healthcare Ltd. | 3.45% |
Lupin Ltd. | 3.04% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.58% |
Dr. Reddy's Laboratories Ltd. | 9.10% |
Divi's Laboratories Ltd. | 8.75% |
Aurobindo Pharma Ltd. | 8.25% |
Cipla Ltd. | 6.92% |
Lupin Ltd. | 5.43% |
Alkem Laboratories Ltd. | 4.05% |
Biocon Ltd. | 3.11% |
Gland Pharma Ltd. | 2.97% |
Mankind Pharma Ltd. | 2.95% |
Name | Dhimant Shah | Dharmesh Kakkad |
Start Date | 06 Feb 2025 | 23 Feb 2021 |
Name
Start Date
Description | The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 18 Oct 2021 | 25 Jun 2018 |
Description
Launch Date